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Introduction
Hepatitis C virus (HCV) infection is a major health problem both 
in developed and developing countries and HCV infection is a global 
blood borne disease that affects almost 3% of the world’s population 
with a morbidity and mortality rate [1]. HCV is an enveloped virus 
with a single-stranded positive RNA and the viral particle consists of a 
nucleocapsid surrounded by an envelope derived from host membranes 
containing RNA genome with approximately 9500 nucleotides (nt). 
Hepatitis C virus (HCV) is a member of the Hepacivirus genus of the 
Flaviviridae family and the viral products (core, E1, E2, NS2, NS3, 
NS4A, NS4B, NS5A, and NS5B) are processed from a 3000-amino acid 
(aa) polyprotein expressed from a single op en reading frame [2,3].
More than 70% of HCV-infected patients develop chronic hepatitis 
and treatments for chronic HCV infection are generally effective in 
only 55% of cases. The efficacy of hepatitis C treatment is less than 
satisfactory and development of an effective vaccine may be essential 
in the control of HCV infection [4]. The E1 and E2 proteins, two 
heavily glycosylated enveloped proteins, which can elicit neutralizing 
antibodies against HCV infection in the host and Core, E1 and E2 
proteins are the major vaccine candidates for vaccination and ELISA 
is one of routine testes which has been used in clinical laboratories 
and different studies to detect the rate of antibody in sera against 
HCV infection [5]. The combination of pegylated interferon α and 
ribavirin is useful to some of treated patients depending on the viral 
or host factors [6]. Additionally, this method needs prolonged therapy, 
sometimes with different side effects and only some of those with 
chronic HCV infections meet the criteria for treatment [7]. Recently, 
production of virus-like particles as a model system for HCV receptor 
binding, cell entry and for vaccination studies is used [8]. Virus-like 
particles are the structural proteins of many viruses which produced 
and self-assembled in the absence of other viral materials and can 
be extracted and purified directly after expression in prokaryote and 
eukaryotic cells, or assembled in vitro from protein subunits purified 
from any recombinant hosts [9,10]. VLPs recognized in the average 
size range of viruses (22-150 nm) and their exact properties depending 
on the viral proteins incorporated, but because they assemble without 
DNA or RNA or genetic materials, VLPs are non-infectious. In this 
study, the HCV virus-like particles (VLPs) obtained from Pichia 
pastoris cells were produced, in order to construct a recombinant 
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Abstract
Background: Hepatitis C virus (HCV) infection is a major health problem both in developed and developing 
countries and HCV infection is a global blood borne disease that affects almost 3% of the world’s population with a 
morbidity and mortality rates. The efficacy of hepatitis C treatment is less than satisfactory and development of an 
effective vaccine may be essential in the control of HCV infection. The E1 and E2 proteins, two heavily glycosylated 
enveloped proteins, which can elicit neutralizing antibodies against HCV infection in the host and Core, E1 and E2 
proteins are the major vaccine candidates for vaccination and ELISA is one of routine testes which has been used in 
clinical laboratories and different studies to detect the rate of antibody in sera against HCV infection.
Aim: Evolvement and gradual development of a useful vaccine can be the main point in the control and 
eradication of hepatitis C virus (HCV) infection. Recent studies have reported that HCV envelope glycoproteins can 
induce neutralizing antibodies against antigen domain of HCV. So HCV envelope proteins are considered as the 
main HCV vaccine candidate.
Methods: In this study, we used Pichia pastoris yeast expression system to express recombinant HCV CoreE1E2 
protein, which consists of Core (269 nt-841nt) E1 (842 nt-1417nt) and E2 (1418 nt-2506nt). The Pichia pastoris 
can produce high level of recombinant HCV CoreE1E2 protein. The protein has glycosylation and also by codon 
optimization based on pichia expression system we could increase the rate of recombinant proteins. Moreover, the 
purified protein can efficiently induce anti-CoreE1E2 antibodies in rabbits, and also by developing homemade ELISA 
kit we can detect antibody of HCV Iranian patients with 1a genotype.
Results: Although little is known about the mechanism of hepatitis C virion assembly, in our study the virus like 
particle of rCoreE1E2 with 70 nm size, were shown by Electron microscopy and have proved the self-assembly in 
vitro in yeast expression system.
Conclusion: These findings indicate that the recombinant CoreE1E2 glycoprotein is effective in inducing 
neutralizing antibodies, and is an influential HCV vaccine candidate.
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HCV Core E1E2 glycoprotein (rCoreE1E2), hoping the rCoreE1E2 
can induce neutralizing antibodies [10]. It has been shown that HCV 
antigens produced in Pichia pastoris induce strong immune responses 
in animals [8,11]. Pichia pastoris is a successful system for production 
of a wide variety of recombinant proteins with its promoter derived 
from the alcohol oxidase I (AOX1) gene of P. pastoris that is suited for 
controlled expression of foreign genes [12,13].
Post-translational modifications performed by higher eukaryotic 
cells such as proteolytic processing, folding, disulfide bond formation 
and glycosylation can be done by P. pastoris. This system is also faster, 
easier, and less expensive than expression systems derived from higher 
eukaryotes such as insect and mammalian tissue culture systems 
and usually gives higher expression levels [13,14]. With P. pastoris, 
heterologous proteins can either be expressed intracellular or secreted 
into the medium and because of self-assembly process which is present 
in recombinant proteins, the virus like particles produced and secreted 
in medium [15]. Secretion requires the presence of a signal sequence 
on the foreign protein to target it to the secretory pathway and the 
S. cerevisiae α factor has been used with the most success [16,17]. 
Expression of different genes in Pichia pastoris cells is a common 
practice in the biopharmaceutical industry. These expression systems 
can have raised error rates in translation due to codon bias, that is, 
preferential use of codons for the same amino acid. As codon bias 
differs between the host organism and the organism from which the 
gene was extracted, substituting synonymous codons can improve 
translational fidelity and in this study codon optimization has been 
used for increasing the protein expression efficacy [18,19].
Method
Study design
Construction of recombinant expression plasmid: The coding 
regions of Core (269 nt-841nt), E1 (842 nt-1417nt) and E2 (1418 nt-
2506nt) were amplified by PCR from infected Iranian patient’s blood 
with HCV (genotype 1a), using primers Core forward [5- TT G A A T 
T C GTC A T G A G C A C G A A T C C T A A A C C T C -3], and E2 
reverse [5- TT G C G G C C G C C G C C T C C G C T T G G G A T A 
T -3], (restriction sites for Xho I , NotI and the reverse stop codon were 
set in primers). In the forward primer for insertion of the CoreE1E2 
gene in the pPICZαA vector it was not necessary to add the Kozak 
sequence because of the presence of the secretion factor in this vector 
and restriction sites added in the 5’ end of primers for insertion into 
the pPICZαA vector and also the poly-histidine (6xHis) tag present 
in the vectors. The CoreE1E2 amplified product was ligated into 
pMD18-T vector (Takara) and then cloned into the XhoI/NotI sites 
of the pPICZαA vector (Invitrogen, Carlsbad, CA, USA) to produce 
pPICZαA-CoreE1E2 according to standard DNA manipulation 
methods. The clones in E. coli TOP 10 were obtained by transformation 
with CaCl2 and selected on low salt LB medium (1% tryptone, 0.5% 
yeast extract, 0.5% NaCl, 2% agar) with Zeocin™ (Invitrogen) (due to 
the presence of the Sh ble gene in the vectors that confers resistance 
to this antibiotic). Recombinants were confirmed by PCR, restriction 
enzyme digestion and sequencing. Then, the recombinant plasmids 
were linearized and electro transformed into the competent P. pichia 
cells. Transformation, screening and recombinant protein expression 
were performed as described by the instruction manual of Pichia 
expression kit (Invitrogen), and the resulting in a recombinant plasmid 
nominated pPICZαA-CoreE1E2.
Expression and purification of rCoreE1E2: The rCoreE1E2 was 
expressed by P. pastoris yeast according to the manufacturer’s manual 
(Multi-Copy Pichia Expression Kit, Invitrogen). Briefly, pPICZαA-
CoreE1E2 was linearized by Pme I and electroporated into P. pastoris 
strain GS115; GS115 (His−, Mut+) transformants were selected on 
Minimal Dextrose (MD) medium plate and confirmed on Minimal 
Methanol (MM) medium plate. Multiple inserted recombinants 
were isolated on Yeast Extract Peptone Dextrose (1% yeast extract, 2% 
peptone, 2% glucose, 1 M sorbitol, and 2% agar) medium plate containing 
Zeocin™ (Invitrogen) at final concentration of 2.0 mg/ml. P. pastoris 
GS115 was also transformed with empty vectors pPICZαA for negative 
control tests. Clones were detected by colony PCR using the conditions 
and primers provided in the EasySelect™ P. pastoris expression kit. The 
primers used for detection anneal in the flanking regions of the insert 
(AOX1 and α-factor). The control strains of the intracellular (GS115/β- 
galactosidase) and extracellular (GS115/albumin) expression provided 
by the EasySelect™ P. pastoris expression kit. After choosing the most 
resistant colon, a single colony of multiple inserted His−, Mut+ GS115 
recombinants was inoculated into 25 mL buffered glycerol complex 
medium (BMGY; 1% yeast extract, 2% peptone, 100 mM potassium 
phosphate (pH 6.0), 1.34% yeast nitrogen base (YNB), 4×10−5 % 
biotin, 1% glycerol) and cultured at 250 rpm and 30ºC until the 
culture medium reached an OD600 of 2–6. The cells were harvested 
by centrifuging at 3,000 rpm for 5 min at room temperature. The 
cell pellet was re-suspended in buffered methanol complex medium 
(BMMY; 1% yeast extract, 2% peptone, 100 mM potassium phosphate, 
pH 6.0, 1.34% YNB, 4x 10-5% biotin, and 0.5% methanol) to an OD600 
of 1.0 and cultured in a 250-mL flask at 250 rpm under 30˚C. Inductive 
expression was carried out with the addition of methanol (0.5%, v/v) 
per 24 h at 30ºC lasted for 3 days. For subsequent analysis of CoreE1E2 
gene expression, samples were taken from cultures every 24 h, including 
aliquots of supernatants and pellets stored at -80°C. The samples were 
collected every 12 h and analyzed by SDS-PAGE and Western blot. For 
extraction and purification of rCoreE1E2, the cells were disrupted by 
glass beads in a TEN buffer (50 mMTris–HCl, pH 8.0, 1 mM EDTA, 
and 150 mM NaCl) and then centrifuged. The rCoreE1E2 mainly 
existed in the deposit with cell fractions, and was not soluble in a TEN 
buffer. The deposit was resuspended in a TEN buffer with 8 M urea and 
centrifuged again. The supernatant was dialyzed against 5 mM Tris–
HCl (pH 9.3) overnight at 4ºC and then clarified by centrifugation at 
12,000×g for 30 min. The supernatant was first loaded to a Q-Sepharose 
Fast Flow column with 20 mMTris–HCl (pH 9.3). After that washing 
with 0.05 M NaCl and 20 mM Tris–HCl (pH 9.3), the rCoreE1E2 was 
eluted with 0.5 M NaCl and 20 mM Tris–HCl (pH 9.3) was performed. 
Then the eluted was loaded to a Phenyl Sepharose Fast Flow column 
with 20 mM Tris–HCl (pH 9.3) and 0.1 M NaCl. The rE1E2 was eluted 
with 20 mMTris–HCl (pH 9.3). The rCoreE1E2 was further purified 
with Sephadex G150 column for removing low molecular weight 
fractions. The purified rCoreE1E2 was dialyzed against 5 mM Tris–HCl 
(pH 9.3) and sterilized with 0.45 µm filter, and then stored at 4ºC.
Protein purification: The secreted Pichia-expressed protein 
in supernatant samples was spun at 15,000 rpm for 30 min. The 
rCoreE1E2 protein was purified from the soluble fraction. Briefly, the 
supernatant was loaded onto Ni-nitrilotriacetic acid (Ni-NTA) agarose 
(Qiagen) in the presence of 0.5% Tween 80 and 40 mM imidazole. The 
column was washed extensively, and the protein was eluted with 1 M 
imidazole. rCoreE1E2 was purified from the insoluble fraction by using 
0.5% N-lauryl sarcosine (Sarkosyl; Sigma Chemical Co., St. Louis, Mo). 
The protein was purified over Ni-NTA-super flow and the Sarkosyl was 
replaced by 0.1% Tween 80. The protein was eluted in the presence of 
200 mM imidazole and 0.1% Tween 80 in phosphate buffer.
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SDS-PAGE and western blotting: Supernatant of yeast culture 
harvested and the cells were harvested and washed twice in TEN 
buffers (50 mM Tris-HCL pH 8.0, 1 mM EDTA, 150 mM NaCl). Cell 
disruption was performed by vortex with glass beads in TEN. The 
lysate was clarified by centrifugation at 12 000 g for 20 min and the 
supernatant and pellet used. The rCoreE1E2 was mixed with sample 
buffer (New England Biolabs, Ipswich, MA, US). The sample was 
boiled for 10 min in the presence of DTT, and around 200 ng was 
loaded on a 4-12% Bis-Tris NuPAGE gel (Invitrogen, Carlsbad, CA, 
US). The primary antibodies against Core E1 E2 were (Santa Cruse); 
the secondary antibody was polyclonal rabbit anti-mouse horse radish 
peroxidase labeled. Staining was done and the molecular weight 
marker was a mix of proteins from Sigma: bovine serum albumin (A-
7517), ovalbumin (A-7642), carbonic anhydrase (C-2273), beta lacto 
globulin (L-4756) and alpha-lacto albumin (L-6385) or the Precision 
and Precision plus Protein Standards (Bio-Rad, Hercules, CA, US, 161-
0374 and 161-0361).
Endoglycosidase digestion assay: Purified rCoreE1E2 was 
digested N-glycosidase F (PNGase F). The digested proteins were 
treated according to the manufacturer’s instructions (New England 
Biolabs) and then analyzed by Western blot with mAb fore Core E1 E2.
Animals, immunization and ELISA: Approximately rCoreE1E2 
(300 g) diluted in 2 ml sterilized 0.9% NaCl used for immunization. 
A New Zealand rabbits was provided from the Experimental Animals 
Center. The rabbit was subcutaneously immunized in multiple sites 
on the back with 0 g (negative control) or 300 g purified rCoreE1E2, 
respectively. Booster injections were given with the same doses at 2, 
3, 4, 5 and 13 weeks later. Sera were obtained every week. The anti-
rCoreE1E2 titers in sera were measured by ELISA. An indirect ELISA to 
measure anti- rCoreE1E2 antibodies in rabbit’s serum was developed. 
In brief, recombinant protein (10 mg/ml) diluted in 50 mM carbonate 
buffer (pH 9.6) was used to coat microtiter plates (Costar, U.S.A.), 
overnight at 4°C. After blocking with 2% (w/v) skim milk powder 
(Oxoid Ltd., England) in PBS with 0.05% (v/v) Tween 20 (Sigma) 
(PBST), pH 7.2 for 1 h at room temperature. The serum samples were 
added in duplicate, either 1/20 in dilution buffer (PBST), containing 
1% (w/v) skim milk powder, to test seroconversion or in a double serial 
starting at 1/50 dilution for titration. They were incubated at 37°C for 
1 h. A horseradish peroxidase (HRP)-labeled anti-rabbit IgG (Sigma) 
was added to 1/10,000 in the dilution buffer. After 1 h of incubation at 
room temperature (RT) and washing, tetramethylbenzidine substrate 
(Sigma) reactions were stopped with 50 ml of 2.5 M H2SO4. Absorbance 
was read at 492 nm in a SensIdent Scan (Merck, Germany). The cut-off 
value used to consider a positive antibody response was established as 
twice the mean of absorbance values of the preimmune sera. Antibody 
titers against rCoreE1E2 were detected as the maximum dilution that 
in ELISA gave for the immunized serum.
Enzyme-linked immunosorbent assays (ELISA) with human 
sera: HCV rCoreE1E2 particles were coated at 1 g/mL in carbonate 
buffer in microtiterplates and were incubated for 2 h at 37ºC. The plates 
washed to remove the non-adsorbed particles and incubated with 
blocking buffer (0.5% casein in PBS). Sera of chronically HCV-infected 
people (Human sera were previously screened for the presence of 
anti-HCV) or sera of healthy persons were added in a dilution of 1:20. 
The plates were washed to remove the non-bound antibodies and the 
plates were incubated with horse radish peroxidase labeled rabbit anti-
human immunoglobulins. The tetramethylbenzidine substrate (Sigma) 
reaction was stopped by addition of 2 N H2SO4 and the absorbance was 
measured at 450 nm. The cutoff value to consider a positive antibody 
response was established as twice the mean OD 492 nm of the negative 
control sera.
Transcriptional analysis of the CoreE1E2 gene: Total RNA 
was extracted from recombinant clones by the total RNA extraction 
kit (Qiagene). The cDNA was synthesized using the IMPROM-II™ 
Reverse Transcription System from Promega (USA). The presence of 
heterologous gene mRNA in Pichia was detected by RT-PCR and Real-
time PCR with Forward primer 5′- TTGGGACATGATGATGAATTGG 
-3′ and Reverse primer 5′- TGCCTGTGGGATTCTAAGC -3′ and 
probe 5`-FAM ACAGCCGCATTGGTTGTCGCC-BHQ1-3`that 
anneal in the internal sequence of the CoreE1E2 genes . Quantitative 
determination of the amplified products was done with the Rotor Gene 
6000 (Corbett Research, Australia).
Electron microscopy: Our supernatant collected and recombinant 
CoreE1E2 was purified and fixed in glutaraldehyde and negatively 
stained with uranyl acetate prior to analysis by transmission electron 
microscopy.
Immunofluorescence: The Pichia pastoris cells after expression of 
rCoreE1E2, were applied to slides, air dried, and fixed with methanol. 
The slides were blocked with bovine serum albumin (BSA) diluted to 1% 
in PBS (PBS-BSA) for 30 min. Primary antibodies diluted in PBS-BSA 
were added to the wells, and the slides were incubated in a humidified 
chamber for 1 h at room temperature. The slides were washed with 
PBS, and fluorescein isothiocyanate-labeled goat anti-mouse antibody 
(Promega) was added and left for 30 min at room temperature. Slides 
were washed and mounted in Vectashield (Vector Labs, Burlingame, 
Calif.) and viewed on an Olympus microscope (Melville, N.Y.).
Codon optimization: The codon-optimized gene was designed 
based on the protein sequence of CoreE1E2 according to the codon bias 
of P. pastoris (http://www.kazusa.or.jp/codon). Codon optimization 
was performed by using the GenScript program. The entire CoreE1E2 
gene with Xho I and Not I restriction sites at each end was designed 
and was in frame with α-factor of pPICZαA vector. The designed 
rCoreE1E2 was synthesized by GenScript (USA).
Sample size: We used one rabbit for Immunization study and 8 
human patients for ELISA evaluation test. 
Data analysis: Data was analyzed by SPSS software version 19.
Results
The continuous coding regions of Core (269 nt-841nt) E1 (842 
nt-1417nt) and E2 (1418 nt-2506nt) were amplified by PCR from 
infected blood by HCV (genotype 1a) and the product (2237 bp) 
was cloned in vector (Figure 1). The colony PCR was done to verify 
the insertion of target gene in vector (Figure 2). After that target 
gene and Ppicza digested by XhoI and NotI enzymes and ligated to 
have one recombinant expression vector (Figure 3). The pPICZαA-
CoreE1E2 was linearized by Pme I and electroporated into P. pastoris 
strain GS115; GS115 (His−, Mut+) and different colony in different 
concentration of Zeocin evaluated and the most resistant colons 
which tolerated 800 and 1600 mic/ml chosen for huge expression 
phase (Figure 4). The rCoreE1E2 protein was purified from the soluble 
fraction by Ni-nitrilotriacetic acid (Ni-NTA) agarose (Qiagen) and 
the purified proteins were studied by SDS-PAGE and Westernblot 
(Figures 5 and 6). Core protein with 20 kDa and E1 protein with 40 
kDa and E2 with 60 kDa were shown. The optimization is one of best 
methods to increase the output of expression in Pichia pastoris. The 
codon-optimized gene was designed based on the protein sequence 
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of CoreE1E2 according to the codon bias of P. pastoris (http://
www.kazusa.or.jp/codon). Possibility of high protein expression level 
is correlated to the value of Codon Adaptation Index (CAI). A CAI 
of 1.0 is considered to be ideal and perfect while a CAI of >0.80 is 
rated as good for expression in the desired Pichia pastoris. As Figure 
7 illustrates the CAI perfect result for expression system is 1.00 
(Figure 7A) and our codon optimization results is 0.85 (Figure 7B). 
The ideal percentage range of GC content is between 30 to 70%. Any 
peaks outside of this range will adversely affect transcriptional and 
translational efficiency. In Figure 8 the average of GC content before 
optimization detected 40.49 (Figure 8A) but after optimization it 
became 45.20 (Figure 8B) and both were shown as GC curves. Figure 9 
reported the percentage distribution of Codon Frequency Distribution 
(CFD) in computed codon quality groups. The value of 100 is set for 
the codon with the highest usage frequency for a given amino acid 
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Figure 1: Schematic vector contained core, E1 and E2 regions of HCV.
 
Figure 2: PCR amplification on Core-E1-E2 gene on patient with HCV 
genotype 1a. (1) 2237 bp gene is the product size of target gene (2) 1000 bp 
ladder.
Figure 3: Colony PCR on 3 different colonies to verify the presence of Core-
E1-E2 cloned gene. (1, 2) do not have the gene and in (3) colony 2237 bp 
target gene amplified (4) Ladder 1000 bp.
Figure 4: Inserted gene Core-E1-E2 in Ppicza is shown. (1) Ladder 1000 bp. 
(2) inserted gene in vector Ppicza. (3) Empty vector without gene.
Figure 5: Culture of colony on medium plate containing Zeocin™ with 800 
mic/ml and 1600 mic/ml concentrations. Highly resistant colony shown and 
selected for expression.
Figure 6: Silver staining of purified recombinant protein. (1) Molecular weight 
Ladder (2) Core (20 kDa), E1 (40 kDa), E2 (60 kDa) proteins.
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in Pichia pastoris (Figure 9A). Codons with values lower than 30 are 
likely to hamper the expression efficiency and as it shows after codon 
optimization the value of Frequency of Optimal Codons (FOP) in our 
gene is acceptable (Figure 9B) and all cordon’s distribution are upper 
than 50%. Interestingly, 60 percent of Codon Frequency Distribution 
is 91-100%, 5 percent is 81-90%, 8 percent is 71-80%, 6 percent is 61-
Figure 7: The distribution of codon usage frequency along the length of Core-E1-E2 to be expressed in Pichia pastoris. CAI of 1.0 is considered to be perfect in the 
desired expression organism (A) and our gene’s CAI = 0.85 is regarded as very good (B) in terms of high gene expression level.
Figure 8: The distribution of GC content frequency along the length of Core-E1-E2 to be expressed in Pichia pastoris. (A)Before optimization it was 40.49 and (B) after 
codon optimization it became 45.20.
Figure 9: The distribution of Codon Frequency Distribution (CFD) frequency along the length of Core-E1-E2 to be expressed in Pichia pastoris. (A)The value of 100 
is set for the codon with the highest usage frequency for a given amino acid in Pichia pastoris and (B)after codon optimization. All the cordon’s distribution are upper 
than 50%.
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70%, 14 percent is 51-60% and 3 percent is 41-50% and no distribution 
lower than 40% was detected. As in Figure 10 is clearly shown, the 
thickness of bands in optimized sample comparing with not-optimizes 
sample, shows that most codons are expressed better in pichia pastoris. 
To determine that the mRNA of recombinant vector are expressed, 
total RNA was extracted from recombinant clones by the total RNA 
extraction and the presence of target mRNA in Pichia was detected by 
RT-PCR and Real-time PCR to detect Core-E1-E2 and housekeeping 
genes (Figure 11). After 30 cycles the housekeeping genes and Core-
E1-E2 gene were detected and analyzed by software. To digest and 
delete carbohydrate residues from recombinant Core-E1-E2, PNGase 
F was used to remove unnecessary N-glycan bands (Figure 12). As 
it is clear, before digestion the presence of smear in lane 1 is present 
but after digestion in lane 2 and also in positive control all bands are 
sharp and Core with 20 kDa and E1 with 40 kDa and E2 with 60 kDa 
is illustrated. Electron microscopy is one of reliable tests to ensure us 
that virus like particle is present in our supernatant. As in Figure 13 
reported, the EM negative staining image shows the particles with 70 
nm size in our sample. Immunofluorescence test by using monoclonal 
Antibodies against Core-E1-E2 was used to show the expression and 
being of recombinant protein in Pichia pastoris cells. In Figure 14, two 
images of positive expression recombinant proteins and normal cell 
without expression are illustrated. For evaluation of efficiency of HCV 
rCoreE1E2 particles against patient sera, we coated them in ELISA 
wells and the sera of some patients were evaluated with international 
QuickTiter™ HCV Core Antigen ELISA Kit (Catalog Numbers VPK-
151) and homemade kit (Figure 15). From those patients, 8 samples 
were shown and interestingly in case number 4,5,6,7 the result of 
our kit is better than standard kit. The comparison between tests was 
carried on 3 times and after analysis by SPSS software the P value<0.001 
was reported.
Number 7 has the highest titer of antibody and in our kit it is 118 
ng/ml but in QuickTiter™ kit it is 90 ng/ml and in case 4 the lowest titer 
 
Figure 10: Western blot of recombinant Core (20 kDa), E1(40 kDa), E2 (60 kDa). (1) Recombinant protein before optimization. (2) Recombinant protein after 
optimization. (3) HCV proteins as Positive control. (4) Negative control. MW is molecular weight markers.
Figure 11: Real-time PCR of Housekeeping gene on left picture and presence of housekeeping gene detected and Target gene of Core-E1-E2 on right picture, after 
30 cycles the result are positive.
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detected and our kit 38 ng/ml and QuickTiter™ kit 22 ng/ml antibody 
level reported. The rCoreE1E2 diluted and used for immunization of 
New Zealand rabbit to show the immunization potential in vivo. The 
rabbit was subcutaneously immunized in multiple sites and after last 
booster injection the titer of antibody checked (Figure 16). The first 
serum collected before immunization and no anti HCV antibody 
detected by ELISA and this sample was kept as zero in data chart. 
After last injection, every week sample shows the raise of antibody for 
example in week 5 the rate of antibody is 49 ng/ml in week 8 is 100 ng/
ml and surprisingly in the week of 10 the antibody titer is 120 ng/ml. 
Discussion
Hepatitis C virus (HCV) infection is a main health problem both in 
developed and developing countries and Iran is a developing country 
which is located in Middle East [20]. One of the aims of HCV research 
is to develop an effective vaccine to produce acceptable immunity 
in human sera against HCV [21]. Last studies have reported that 
the HCV glycoproteins can induce neutralizing antibodies, making 
them as a candidate for HCV vaccine [22]. In our current study, the 
sample of HCV virus (genotype 1a) diagnosed and used as a temple 
for amplification and expression. Due to the sample of Iranian HCV 
patient, we proposed an efficient vaccine candidate for more research. 
Although some research showed that it was difficult to express HCV 
envelope proteins by P.pastoris yeast, we could express HCV rCoreE1E2 
by Pichia pastoris yeast expression system which was used in our study 
is pPICZαA vector (Invitrogen, Carlsbad, CA, USA) and this vector 
has α-factor to help us to express and secret recombinant protein in 
high volume both in intra and extracellular [13,23]. Therefore, Western 
blotting using anti-Core/E1/E2 mAbs demonstrated a different bands 
for Core 20 kDa, E1 40 kDa, E2 60 kDa in yeast-expressed system [24]. 
The glycans of HCV envelope proteins are very critical for structures, 
functions and antigenicity. Using eukaryotic expression system for HCV 
envelope glycoproteins can help us to make native shape and function 
 
 
 
 
 
 
 
 
 
 
Figure 12: Western blot of recombinant Core (20 kDa), E1(40 kDa), E2 (60 
kDa). (1) Recombinant protein before PNGaseF and it is smear like and heavy 
with N-glucan bands. (2) Recombinant protein after PNGaseF without extra 
N-glucan linkages and sharp bands. (3) HCV proteins as Positive control. (4) 
Negative control. MW is molecular weight markers.
Figure 13: Virus like particle are shown with the size of 70 nm in negative 
staining EM as a golden standard method to verify the presence of 
recombinant particles. Bar=100nm.
 
Figure 14: Immunofluorescence test on pichia pastoris cells to show that 
expressed proteins are present in cells. (1) Positive cells in expression of 
recombinant Core E1 E2 proteins. (2) Control of pichia pastoris cells without 
expression vector.
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Figure 15: Our ELISA kit with recombinant Core-E1-E2 is compared with 
standard international kit. The blue bar is the result of antibody of patients 
Antigen ELISA Kit QuickTiter™ HCV Core and another bar is antibody titers of 
patients with our ELISA kit. In this chart 8 samples are shown and in number 
4,5,6,7 the result of homemade kit is better than QuickTiter™ kit. Data were 
reapeted 3 times and results were the same.
Figure 16: Antibody titers in rabbit after last injection of recombinant Core-
E1-E2 protein is shown and 10 weeks after last injection the titer of 120 ng/
ml was reported.
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for our recombinant proteins [25]. P. pastoris yeast can synthesize 
and process rCoreE1E2 carrying glycans which could be digested by 
PNGase F and this glycozilation is similar to some of original HCV 
envelope glycoproteins. The truth is that glycans of rCoreE1E2 should 
be different to native CoreE1E2 because of the difference between 
yeast and mammalian cells [26]. The removes all three types of amino-
linked glycans, high mannose- type glycans, hybrid-type glycans, and 
complex- type glycans. In P. pastoris cells, the N-glycosylation pathway 
is similar to the pathway in human cells except that P. pastoris cells 
have just high mannose structures [27]. Enzymatic deglycosylation 
with PNGase F resulted that the glycosylated smeared band disappear 
and sharp band with less molecular weight which corresponds to 
nonglycosylated proteins remain, indicating that the multiple bands 
arise by different degrees of N-glycosylation. The yeast expressed 
rCoreE1E2 has all potential N-glycosylation sites occupied [28].
We reported that codon optimization leads to increase expression 
of recombinant Core-E1-E2 in P. pastoris and also we evaluated the 
utility of codon optimization to improve the expression of Core-
E1-E2 in P. pastoris. We designed the Core-E1-E2 gene by choosing 
the most preferred codons, while avoiding the formation of stable 
secondary structures in the corresponding mRNA sequence. 
Therefore, codon optimization moderately increased the expression 
level and our data was similar with other optimization studies which 
show increase of efficacy by codon optimization. The translational 
hypothesis related to translation initiation and elongation rates has 
been well accepted for explaining the codon usage bias in eukaryotes. 
Although the mRNA levels were similar between the native and the 
optimized constructs, suggesting that the increased expression is 
attributable to the enhancement of posttranscriptional processing 
(data not shown). As the, we expect that the increased expression by 
codon optimization should be mainly due to the enhanced translation 
elongation instead of translation initiation. It seems that other factors 
like protein folding within the endoplasmic reticulum and secretion 
signal processing may be important in secretion ability [29]. Moreover, 
in our study the native gene employs tandem rare codons that can 
reduce the efficiency of translation or even disengage the translational 
machinery. We changed the codon usage bias in Pichia pastoris by 
to 0.85. GC content and unfavorable peaks have been optimized to 
prolong the half-life of the mRNA. The Stem-Loop structures, which 
impact ribosomal binding and stability of mRNA, were broken [30]. 
In addition, our optimization process has screened and successfully 
modified those negative cis-acting sites. In other past researches 
different parts of HCV glycoproteins were used for immunization in 
mice, goat, sheep and raising antibody detected but whole CoreE1E2 
which is more immunogenic was not shown. In this study, the strategy 
of inducing broadly neutralizing antibodies is probably successful 
to produce anti HCV glycoprotein antibody as it succeeds in rabbit 
and our rCoreE1E2 can induce high humeral immune response and 
it can be one step forward for evaluation of HCV vaccine for in vivo 
research. The immune reactivity of rCoreE1E2 particles was tested by 
international ELISA Kit QuickTiter™ HCV and homemade ELISA 
kit, using sera from chronically HCV-infected persons. Indicating the 
epitopes presented by our particle’s conformation is very analogous 
with the original HCV particle. The evaluation of human sera, showing 
anti-HCV positive sera against rCoreE1E2 proteins demonstrated that 
anti-HCV positive sera recognized our recombinant peptide by ELISA 
and even in some cases our results were better than international 
kit (P.value<0.001). Based on conformation, we have shown that 
recombinant Core-E1-E2 proteins can be expressed from a yeast system 
and purified to homogeneity [31,32]. Moreover our data shows that 
human sera is anti-recombinant protein and can neutralize our protein 
in ELISA system which is better result than other researches and also 
because we produced whole CoreE1E2 protein of HCV virus, all the 
immunogenic sites are in our recombinant protein which has not been 
in other studies. These recombinant proteins efficiently self-assemble 
in vitro into virus like particles with a regular, spherical morphology. 
These particles have a modal diameter centered about 70 nm and were 
shown with negative staining by Electron microscopy and also because 
CoreE1E2 assembled together the size of particle increased which is 
similar to other studies base on HCV particles in vivo and in vitro 
[21,23,33]. In conclusion, the expression of the HCV structural proteins 
in P. pastoris would be useful for studying the mechanisms of HCV 
processing, morphogenesis, immunity and assembly. Natural HCV 
structural proteins are not useful for developing vaccines or specific 
anti-sera because the virus concentrations in the infectious materials 
are very low. Therefore, recombinant HCV structural proteins are 
useful as immunogens. For the development of preventive vaccines 
and therapeutic treatments against HCV, the rCoreE1E2 protein 
might be a crucial element and the results obtained in this work may 
therefore contribute to this effort. These recombinant proteins may be 
useful targets for HCV vaccine candidates. Moreover, P. pastoris yeast 
expression system is an efficient eukaryotic expression system and we 
believe that the P. pastoris yeast-expressed rCoreE1E2 is a promising 
HCV vaccine candidate for industrial purpose.
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